Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | December 01, 2025 | December 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiNK Therapeutics, Inc.
Report date December 01, 2025 · Filed December 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,126 |
Reported balance
After 2025-12-01 transaction · row 1
1 source rowRow 1 · 2025-12-01 · Grant · Acquired 1,218 · Balance 19,126 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2025 Filed Dec 3, 2025 16:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,218 | $11.09 | $13,507.62 |
DisclosureSEC source: 0001193125-25-306676 · ownership.xml · nonDerivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,126 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 16:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 3,225 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001193125-25-201318 · ownership.xml · derivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,225 Underlying: Common Stock · 3,225 shares Expires 2035-09-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 17:30 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 975 | $13.86 | $13,513.50 |
DisclosureSEC source: 0001193125-25-195091 · ownership.xml · nonDerivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,908 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 16:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,883 | $7.17 | $13,501.11 |
DisclosureSEC source: 0000950170-25-081609 · ownership.xml · nonDerivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,647 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 16:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,536 | $8.79 | $13,501.44 |
DisclosureSEC source: 0000950170-25-033540 · ownership.xml · nonDerivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,764 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2024 Filed Dec 9, 2024 16:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 12,286 | $0.73 | $8,968.78 |
DisclosureSEC source: 0000950170-24-134524 · ownership.xml · nonDerivative · entry 1 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,286 F2 · price: Dr. Kadlec was granted restricted stock unites ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| October 30, 2024 Filed Dec 9, 2024 16:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option · Derivative | 41,745 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-24-134524 · ownership.xml · derivative · entry 2 Kadlec Robert Peter · CIK 0002047073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,745 Underlying: Common Stock · 41,745 shares Expires 2034-10-30 F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on October 30, 2024 and will vest in three equal annual installments on each of October 30, 2025, 2026 and 2027 (provided Dr. Kadlec maintains a service relationship with the company through each such vesting date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.